Dopamine Agonists, DRIs Similar for QoL in Parkinson Disease
No measurable difference in patient-rated quality of life seen for dopamine agonists versus dopamine reuptake inhibitors as adjuvant therapy
Parkinsonism
Novel Pramipexole-Rasagiline Combo Promising for Early Parkinson Disease
The fixed-dose combination therapy was found to be superior to each component.
AAN Updates Recommendations for Early Parkinson Disease Treatment
Counseling should be provided to individuals with early Parkinson disease on the benefits and risks of initiating treatment.
Focused Ultrasound Device Approved for Advanced Parkinson Disease
Patients are awake and responsive during the whole treatment duration.
Continuous SC Infusion Therapy Bests Oral Levodopa/Carbidopa in Parkinson Trial
The randomized, double-blind, double-dummy, active-controlled study compared ABBV-951 via continuous SC infusion to oral levodopa/carbidopa.
Oral Inosine Does Not Slow Progression of Early Parkinson Disease
No significant difference seen in rate of clinical disease progression or in secondary efficacy outcomes versus placebo
MPR Weekly Dose Podcast Episode 87
This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there’s a new treatment approved for Progressive Familial Intrahepatic Cholestasis.
Stem Cell Therapy Gets Fast Track Status for Parkinson Disease
DA01 is an investigational pluripotent stem cell-derived dopaminergic neuron therapy designed to replace the midbrian dopaminergic neurons lost in Parkinson disease.
Benefits of Deep Brain Stimulation Persist in Parkinson Disease
Reductions in time spent with dyskinesia, time spent in the off state, and in dopaminergic drugs sustained for more than 15 years.
NeuroSphere Virtual Clinic Allows for Remote Neuromodulation Therapy Management
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.
